Studying the Complex Formation of Sulfonatocalix[4]naphthalene and Meloxicam towards Enhancing Its Solubility and Dissolution Performance.
dissolution
inclusion complexes
meloxicam
phase solubility
physicochemical characterization
sulfonatocalix[4]naphthalene
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
30 Jun 2021
30 Jun 2021
Historique:
received:
10
06
2021
revised:
25
06
2021
accepted:
28
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
The interaction between meloxicam and sulfonatocalix [4] naphthalene was investigated to improve the meloxicam solubility and its dissolution performance. Solubility behavior was investigated in distilled water (DW) and at different pH conditions. Besides, solid systems were prepared in a 1:1 molar ratio using coevaporate, kneading, and simple physical mixture techniques. Further, they were characterized by PXRD, FT-IR, DCS, and TGA. In vitro dissolution rate for coevaporate, kneaded, and physical mixture powders were also investigated. Solubility study revealed that meloxicam solubility significantly increased about 23.99 folds at phosphate buffer of pH 7.4 in the presence of sulfonatocalix [4] naphthalene. The solubility phase diagram was classified as A
Identifiants
pubmed: 34209201
pii: pharmaceutics13070994
doi: 10.3390/pharmaceutics13070994
pmc: PMC8309163
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Molecules. 2018 May 11;23(5):
pubmed: 29751694
AAPS PharmSciTech. 2019 Dec 17;21(1):26
pubmed: 31848763
J Pharm Sci. 2020 Jul;109(7):2237-2251
pubmed: 32320670
J Agric Food Chem. 2007 May 2;55(9):3535-9
pubmed: 17407323
J Pharm Pharmacol. 2018 Feb;70(2):250-258
pubmed: 29193077
J Org Chem. 2011 Feb 4;76(3):971-3
pubmed: 21229978
Pharmaceuticals (Basel). 2020 Dec 05;13(12):
pubmed: 33291402
Pharmaceutics. 2018 Jul 19;10(3):
pubmed: 30029516
Biomolecules. 2019 Mar 05;9(3):
pubmed: 30841659
Expert Opin Drug Metab Toxicol. 2005 Dec;1(4):739-51
pubmed: 16863437
Int J Pharm. 2004 Apr 1;273(1-2):57-62
pubmed: 15010130
Colloids Surf B Biointerfaces. 2020 Jul 17;195:111262
pubmed: 32736123
J Pharm Pharmacol. 2004 Jun;56(6):703-8
pubmed: 15231034
Front Chem. 2019 Oct 09;7:668
pubmed: 31649920
Int J Oral Maxillofac Surg. 2006 Jul;35(7):613-7
pubmed: 16540287
J Pharm Pharmacol. 1975 Jan;27(1):48-9
pubmed: 235616
Inflamm Res. 1998 Jun;47(6):270-6
pubmed: 9683035
Chem Rev. 2014 Nov 12;114(21):10940-75
pubmed: 25247843
Carcinogenesis. 1998 Dec;19(12):2195-9
pubmed: 9886578
Iran J Pharm Res. 2011 Fall;10(4):685-94
pubmed: 24250403
Eur J Pharm Biopharm. 2004 Nov;58(3):629-36
pubmed: 15451538
AAPS PharmSciTech. 2008;9(1):314-21
pubmed: 18446497
AAPS PharmSciTech. 2018 Oct;19(7):2948-2960
pubmed: 30027418
Nature. 2001 Jul 26;412(6845):397-400
pubmed: 11473302
J Pharm Sci. 2018 Jan;107(1):446-452
pubmed: 28551427
Org Lett. 2012 Jul 6;14(13):3530-3
pubmed: 22724527
Mol Pharm. 2012 Jul 2;9(7):2094-102
pubmed: 22642304
J Pharm Biomed Anal. 2004 Apr 1;35(1):75-86
pubmed: 15030882
Pharm Dev Technol. 2018 Jun;23(5):496-503
pubmed: 28489472
Cryobiology. 2004 Aug;49(1):62-82
pubmed: 15265717
Int J Mol Sci. 2019 Feb 02;20(3):
pubmed: 30717337
J Am Chem Soc. 1988 Aug 1;110(18):6153-62
pubmed: 22148794
Eur J Pharm Biopharm. 2005 May;60(1):39-46
pubmed: 15848054
Chem Soc Rev. 2017 May 9;46(9):2376-2377
pubmed: 28443886
Pharmaceuticals (Basel). 2020 Sep 29;13(10):
pubmed: 33003610
Polymers (Basel). 2019 Dec 18;12(1):
pubmed: 31861423
Arch Pharm Res. 2007 Feb;30(2):215-21
pubmed: 17366744